...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pharmacogenomics >DNA methylation as a marker of response in rheumatoid arthritis
【24h】

DNA methylation as a marker of response in rheumatoid arthritis

机译：DNA甲基化作为类风湿性关节炎反应的标志物

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Rheumatoid arthritis (RA) is a complex disease affecting approximately 0.5-1% of the population. While there are effective biologic therapies, in up to 40% of patients, disease activity remains inadequately controlled. Therefore, identifying factors that predict, prior to the initiation of therapy, which patients are likely to respond best to which treatment is a research priority and DNA methylation is increasingly being explored as a potential theranostic biomarker. DNA methylation is thought to play a role in RA disease pathogenesis and in mediating the relationship between genetic variants and patient outcomes. The role of DNA methylation has been most extensively explored in cancer medicine, where it has been shown to be predictive of treatment response. Studies in RA, however, are in their infancy and, while showing promise, further investigation in well-powered studies is warranted.
机译：类风湿性关节炎（RA）是一种影响人口约0.5-1％的复杂疾病。 虽然有有效的生物疗法，在高达40％的患者中，疾病活动仍然不充分控制。 因此，在治疗开始之前识别预测的因素，患者可能最佳地响应哪种治疗是一种研究优先权，并且DNA甲基化越来越多地被探索为潜在的治疗生物标志物。 DNA甲基化被认为在RA病发病机制中发挥作用，并在介导遗传变异和患者结果之间的关系。 DNA甲基化的作用在癌症医学中最广泛地探索，其中已被证明是预测治疗反应的预测。 然而，RA的研究在他们的初期，并且在展示希望的同时，有必要进一步调查良好的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号